These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15242682)

  • 41. Exploring the anti-tumour activity of bisphosphonates in early breast cancer.
    Winter MC; Holen I; Coleman RE
    Cancer Treat Rev; 2008 Aug; 34(5):453-75. PubMed ID: 18423992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS; Fayans EP
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bisphosphonates and bone metastases: current status and future directions.
    Krempien R; Niethammer A; Harms W; Debus J
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):295-305. PubMed ID: 15877526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
    Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S25-30. PubMed ID: 18486347
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence.
    Daniele G; Giordano P; De Luca A; Piccirillo MC; Di Maio M; Del Giudice A; De Feo G; Bryce J; Lamura L; Vecchione A; Normanno N; Perrone F
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):299-307. PubMed ID: 21342047
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle.
    Bertoldo F; Santini D; Lo Cascio V
    Nat Clin Pract Oncol; 2007 Dec; 4(12):711-21. PubMed ID: 18037875
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging strategies in bone health management for the adjuvant patient.
    Coleman RE
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S11-6. PubMed ID: 18068485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.
    Saad F; Lipton A
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S17-23. PubMed ID: 18068486
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
    Machado M; Cruz LS; Tannus G; Fonseca M
    Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of bisphosphonates in the management of bone metastases in prostate cancer.
    Saad F; Chi K; Fleshner N
    Can J Urol; 2004 Oct; 11(5):2376-82. PubMed ID: 15576002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA; Rodan GA
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.
    Tanaka T; Kawashima H; Ohnishi K; Matsumura K; Yoshimura R; Matsuyama M; Kuratsukuri K; Nakatani T
    Anticancer Res; 2009 Apr; 29(4):1089-94. PubMed ID: 19414350
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration.
    Cheng YY; Huang L; Kumta SM; Lee KM; Lai FM; Tam JS
    Ultrastruct Pathol; 2003; 27(6):385-91. PubMed ID: 14660277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Bisphosphonates and bone metastases of solid tumors: therapeutic interest despite its anti-resorptive properties].
    Clézardin P
    Prog Urol; 2003 Apr; 13(2 Suppl 1):28-35. PubMed ID: 12815807
    [No Abstract]   [Full Text] [Related]  

  • 59. Nitrogen-containing bisphosphonates and cancer immunotherapy.
    Clézardin P; Massaia M
    Curr Pharm Des; 2010; 16(27):3007-2014. PubMed ID: 20722623
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The chemistry of bisphosphonates: from antiscaling agents to clinical therapeutics.
    Widler L; Jahnke W; Green JR
    Anticancer Agents Med Chem; 2012 Feb; 12(2):95-101. PubMed ID: 21864230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.